


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: STROBEL, et al.

Serial No.: 10/632,083

Filed: July 31, 2003

Title: **ACYLATED, HETEROARYL-CONDENSED
CYCLOALKENYLAMINES AND THEIR USE
AS PHARMACEUTICALS**



Examiner:

Group Art Unit.:


POWER OF ATTORNEY FOR PATENT APPLICATION

Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

We, Markus Jacobi and Hans-Jürgen Fischer, Authorized Signatories of Aventis Pharma Deutschland GmbH, Assignee of the above-identified Application, hereby appoint the attorneys and/or agents associated with the Customer No.(s) provided below as attorneys and/or agents with full power to prosecute this application on behalf of Assignee and to transact all of Assignee's business in connection with the above-identified Application in the Patent and Trademark Office:


Customer No.: 005487

Effective Date: July 31, 2003

By: 
Markus Jacobi

Title: Prokurist

Date: November 21, 2003

By: 
Hans-Jürgen Fischer

Title: Handlungsbevollmächtigter

Date: November 21, 2003

Address correspondence and telephone calls to:
Raymond S. Parker, III, Ph.D., Reg. No. 34,893
Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-5674
Telefax (908) 231-2626



2002/00574

UNITED STATES OF AMERICA

**DECLARATION
FOR PATENT APPLICATION**

As a below named inventor(s), I/We hereby declare that:

My/Our residence(s), post office address(es) and citizenship(s) are as stated below my name(s).
I/We verily believe I am/we are the original, first and sole/joint inventor(s) of the subject matter which is claimed
and for which a patent is sought on the invention entitled:

**ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS
PHARMACEUTICALS**

and the specification of which ☐ is attached hereto (Aventis Docket No. **DEAV2002/0057 US NP**)
(check one) ☒ was filed on **July 31, 2003** as U.S. Application Number **10/632,083**
and was amended on _____ (if applicable).
☐ was described and claimed in PCT Int'l Application Number _____ filed on
and as amended under PCT Article 19 on _____ (if any).

I/We hereby state that I/We have reviewed and understand the contents of the above identified specification,
including the claims as amended by any amendment referred to above.
I/We acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me/us to
be material to patentability as defined in 37 C.F.R. 1.56.

- ☒ I/We hereby claim foreign priority benefits under Title 35, United States Code §119(a)-(d) or 365 (b) of any foreign
application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at
least one other country other than the United States of America, listed below and having a filing date before that of
the application on which priority is claimed. I/We have also identified below any foreign application for patent or
inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Priority:	02017586.5 Number	European Country	07/08/2002 Day/Month/Year Filed
----------------------	-----------------------------	----------------------------	---

Prior Foreign Appn(s):	Number	Country	Day/Month/Year Filed
------------------------------	--------	---------	----------------------

- ☒ I/We hereby claim the benefit under Title 35, United States Code §119(e) of any United States Provisional
application(s) listed below:

60/432,441 Number	December 11, 2002 Filing Date
-----------------------------	---

- ☐ I/We hereby claim the benefit under Title 35, United States Code §120 or 365(c) of any United States
application(s) or international application designating the United States listed below and, insofar as the subject
matter of each of the claims of this application is not disclosed in the prior United States application in the manner
provided by the first paragraph of Title 35, United States Code §112, I/We acknowledge the duty to disclose
information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which
became available between the filing date of the prior application and the national or PCT international filing date of
this application.

Application Serial No.	Filing Date	Status (Patented, Pending)
------------------------	-------------	----------------------------

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventors(s): ☐ Additional names and signatures are attached.

1. Full name: Hartmut STROBEL

Signature: 

Date: 18 Nov 2003

Country of Citizenship: GERMANY


Residence: Liederbach, Germany

(City and State/City and Country only)

P. O. Address: Erlenweg 22

65835 Liederbach, Germany

2. Full name: Paulus WOHLFART

Signature: 

Date: 18/11/03

Country of Citizenship: GERMANY

Residence: Bensheim, Germany

(City and State/City and Country only)

P. O. Address: Bertolt-Brecht-Ring 16c

64625 Bensheim, Germany

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206

P.O. Box 6800

Mail Code D-303A

Bridgewater, NJ 08807-0800

Telephone (908) 231-3638

Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0057 US NP